ABEO - Abeona Therapeutics Inc.
| Previous Close | 7.26 |
| Open | 7.19 |
| Bid | 6.93 x 800 |
| Ask | 6.94 x 900 |
| Day's Range | 6.87 - 7.28 |
| 52 Week Range | 6.26 - 22.00 |
| Volume | 205,016 |
| Avg. Volume | 658,327 |
| Market Cap | 330.668M |
| Beta (3Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.33 |
- GlobeNewswire•14 days ago
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
- Simply Wall St.•28 days ago
How Should Investors Feel About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) CEO Pay?
Tim Miller has been the CEO of Abeona Therapeutics Inc. (NASDAQ:ABEO) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Insider Monkey•last month
Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Zacks•last month
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•last month
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- GlobeNewswire•2 months ago
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS.
- Zacks•2 months ago
Moving Average Crossover Alert: Abeona Therapeutics
Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Abeona Therapeutics Announces CEO Transition
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the immediate termination of its Chief Executive Officer, Dr. Carsten Thiel due to personal misconduct that violated the Company’s Code of Business Conduct and Ethics.
- GlobeNewswire•2 months ago
Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
NEW YORK and CLEVELAND, Nov. 13, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
Q3 2018 Abeona Therapeutics Inc Earnings Call
- Zacks•2 months ago
Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Abeona Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 34 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•2 months ago
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage.
- Simply Wall St.•2 months ago
What Kind Of Share Price Volatility Should You Expect For Abeona Therapeutics Inc (NASDAQ:ABEO)?
If you own shares in Abeona Therapeutics Inc (NASDAQ:ABEO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•3 months ago
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20.
- PR Newswire•3 months ago
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
ROCKVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1 (CLN1 Disease), and Juvenile Batten Disease, also known as neuronal ceroid lipofuscinosis type 3 (CLN3 Disease).
Market Realist•4 months agoHow Abeona Therapeutics Stock Is Doing
Yesterday, Abeona Therapeutics (ABEO) stock closed at $13, ~75% below its 52-week high of $22.75 on October 11, 2017. This month, Abeona stock has fallen 15% from $15.40 on August 31. Abeona’s 52-week low is $10.50, which it reached on February 15.
- Simply Wall St.•4 months ago
When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Become Profitable?
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. With the latest financial yearRead More...
Market Realist•4 months agoAnalysts Still Bullish about BioLife Solutions
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
